Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

TCON

TRACON Pharmaceuticals Inc

Apr 24 • 04:00PM ET

1.89

Dollar change +0.04
Percentage change 2.16	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-5.20	Insider Own	7.89%	Shs Outstand	2.21M	Perf Week	-17.47%
Market Cap	4.31M	Forward P/E	-	EPS next Y	-3.69	Insider Trans	0.00%	Shs Float	2.10M	Perf Month	-79.46%
Income	-3.59M	PEG	-	EPS next Q	-1.19	Inst Own	11.02%	Short Float	4.52%	Perf Quarter	-46.55%
Sales	12.04M	P/S	0.36	EPS this Y	-115.76%	Inst Trans	-	Short Ratio	0.40	Perf Half Y	-38.60%
Book/sh	-0.37	P/B	-	EPS next Y	22.33%	ROA	-24.26%	Short Interest	0.09M	Perf Year	-94.69%
Cash/sh	3.75	P/C	0.50	EPS next 5Y	-	ROE	-	52W Range	1.59 - 36.80	Perf YTD	-46.03%
Dividend Est.	-	P/FCF	1.17	EPS past 5Y	61.51%	ROI	-	52W High	-94.86%	Beta	1.24
Dividend TTM	-	Quick Ratio	0.89	Sales past 5Y	-40.00%	Gross Margin	99.88%	52W Low	18.87%	ATR (14)	0.88
Dividend Ex-Date	-	Current Ratio	0.89	EPS Y/Y TTM	81.52%	Oper. Margin	-57.27%	RSI (14)	34.28	Volatility	10.41% 25.15%
Employees	17	Debt/Eq	-	Sales Y/Y TTM	-100.00%	Profit Margin	-29.79%	Recom	1.67	Target Price	37.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	103.48%	Payout	-	Rel Volume	0.28	Prev Close	1.85
Sales Surprise	103.00%	EPS Surprise	112.50%	Sales Q/Q	-	Earnings	Mar 05 AMC	Avg Volume	235.61K	Price	1.89
SMA20	-55.73%	SMA50	-62.20%	SMA200	-57.39%	Trades		Volume	65,774	Change	2.16%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Upgrade	BTIG Research	Neutral → Buy	$14
Feb-10-21	Initiated	Maxim Group	Buy	$24
Dec-23-19	Reiterated	H.C. Wainwright	Buy	$15 → $18
Mar-01-19	Reiterated	Needham	Buy	$7
Jun-13-17	Reiterated	Stifel	Buy	$14 → $6
Dec-21-16	Initiated	Jefferies	Buy	$10
Feb-01-16	Resumed	Oppenheimer	Outperform
Jul-29-15	Initiated	ROTH Capital	Buy	$18
Mar-02-15	Reiterated	Stifel	Buy	$16 → $20
Mar-02-15	Reiterated	Oppenheimer	Outperform	$22 → $26
Feb-24-15	Initiated	Stifel	Buy	$16
Feb-24-15	Initiated	Oppenheimer	Outperform	$22

Show Previous Ratings

Apr-10-24 06:30AM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024 (InvestorPlace) -10.47%
Apr-08-24 09:10AM	TRACON Pharmaceuticals Announces Reverse Stock Split (GlobeNewswire) -24.79%
Apr-03-24 08:00AM	TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned (GlobeNewswire) -47.18%
Mar-07-24 10:03AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript (Insider Monkey) +18.02%
Mar-05-24 04:29PM	Tracon: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Loading…
04:02PM	TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-28-24 04:02PM	TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024 (GlobeNewswire)
Dec-20-23 08:00AM	TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial (GlobeNewswire)
Nov-21-23 07:55AM	Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today? (InvestorPlace) +25.07%
07:32AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Nov-20-23 08:00AM	TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment (GlobeNewswire)
Nov-13-23 09:29AM	Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today? (InvestorPlace) -7.08%
Nov-12-23 08:47AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 07:45AM	Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today? (InvestorPlace) +43.94%
Nov-09-23 04:58PM	Tracon: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Loading…
04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-23 04:02PM	TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023 (GlobeNewswire) +11.35%
Sep-18-23 08:00AM	TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned (GlobeNewswire)
Sep-05-23 04:02PM	TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace)
Aug-15-23 08:43AM	Q2 2023 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.95%
Aug-14-23 07:00PM	Tracon: Q2 Earnings Snapshot (Associated Press Finance) -9.66%
04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-02-23 04:05PM	TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023 (GlobeNewswire) +14.06%
Jul-11-23 08:00AM	TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma (GlobeNewswire) +5.52%
Jun-20-23 08:00AM	TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial (GlobeNewswire)
Jun-16-23 08:00AM	TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference (GlobeNewswire)
Jun-15-23 08:00AM	TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma (GlobeNewswire) -5.91%
Jun-02-23 08:00AM	TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire) +7.93%
May-30-23 08:00AM	TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting (GlobeNewswire)
11:24AM	Loading…
May-11-23 11:24AM	Q1 2023 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.14%
May-10-23 04:38PM	Tracon: Q1 Earnings Snapshot (AP Finance)
04:02PM	TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-23 04:02PM	TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023 (GlobeNewswire) +5.19%
Apr-25-23 07:41AM	TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab (GlobeNewswire) -46.63%
Apr-06-23 08:30AM	Runway Growth Finance Corp. Provides First Quarter 2023 Portfolio Update (GlobeNewswire) +6.19%
Mar-14-23 12:00PM	Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade (Zacks) +6.16%
Mar-10-23 02:26AM	TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript (Insider Monkey) +8.33%
Mar-09-23 05:49AM	Q4 2022 TRACON Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-08-23 04:02PM	TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -8.00%
Feb-28-23 04:02PM	TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023 (GlobeNewswire)
Jan-20-23 06:55AM	Daily Vickers Top Buyers & Sellers for 01/20/2023 (Argus Research)
Jan-10-23 08:30AM	Runway Growth Finance Corp. Provides Fourth Quarter 2022 Portfolio Update (GlobeNewswire)
Dec-27-22 08:00AM	TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023 (GlobeNewswire) +10.34%
Dec-14-22 11:29AM	TRACON Touts Encouraging Objective Response Rates For Mid-Stage Cancer Study (Benzinga)
08:00AM	TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial (GlobeNewswire)
Nov-21-22 08:00AM	TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma (GlobeNewswire)
Nov-14-22 04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +9.03%
Oct-31-22 08:00AM	TRACON to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 14, 2022 (GlobeNewswire)
Oct-06-22 08:30AM	Runway Growth Finance Corp. Provides Third Quarter 2022 Portfolio Update (GlobeNewswire) +6.63%
08:00AM	TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned (GlobeNewswire)
Sep-14-22 08:00AM	TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS (GlobeNewswire)
Sep-07-22 08:00AM	TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Sep-06-22 08:00AM	TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital (GlobeNewswire) -5.53%
Aug-29-22 08:00PM	US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (Business Wire)
11:45AM	TRACON Secures FDA Nod For Early-Stage Study In Soft-Tissue Cancer (Benzinga)
08:00AM	TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (GlobeNewswire)
Aug-10-22 04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +10.11%
08:00AM	TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial (GlobeNewswire)
Aug-08-22 08:00AM	TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab (GlobeNewswire)
Jul-27-22 08:05AM	TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022 (GlobeNewswire) +6.32%
Jul-26-22 08:05AM	TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter (GlobeNewswire)
Jun-02-22 08:05AM	TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-16-22 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +15.57%
May-11-22 04:02PM	TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-22 08:05AM	TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022 (GlobeNewswire)
Apr-19-22 08:05AM	TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K. (GlobeNewswire)
Apr-08-22 05:02PM	Recession Fears are Creating a Golden Opportunity for Biotech Stocks (InvestorPlace)
Mar-23-22 08:05AM	TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference (GlobeNewswire) +9.16%
Mar-15-22 04:02PM	TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-11-22 08:05AM	TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) -6.85%
Mar-10-22 08:05AM	TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol (GlobeNewswire) +18.22%
Mar-04-22 08:05AM	TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022 (GlobeNewswire)
Feb-02-22 08:05AM	TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute (GlobeNewswire)
Jan-05-22 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire) -9.25%
Dec-27-21 08:00AM	TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial (GlobeNewswire) -20.16%
Nov-29-21 08:05AM	TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China (GlobeNewswire)
Nov-11-21 08:05AM	TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference (GlobeNewswire)
Nov-03-21 04:02PM	TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-27-21 08:05AM	TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021 (GlobeNewswire)
Oct-13-21 08:00AM	TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors (GlobeNewswire)
Oct-11-21 01:27PM	TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications (Benzinga) +7.96%
08:00AM	TRACON Pharmaceuticals and Eucure Biopharma, a Subsidiary of Biocytogen, Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001 (GlobeNewswire)
Sep-13-21 08:05AM	TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit (GlobeNewswire)
Sep-07-21 08:05AM	TRACON Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
07:29AM	TRACON Pharmaceuticals on the Fast Track for Sarcoma Injection Treatments (Benzinga)
Sep-02-21 08:05AM	TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference (GlobeNewswire) +6.04%
Aug-11-21 04:02PM	TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-09-21 08:05AM	TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial (GlobeNewswire)
Aug-03-21 08:05AM	TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire) -10.05%
Jul-28-21 08:05AM	TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021 (GlobeNewswire)
Jul-21-21 10:30PM	TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million (GlobeNewswire)
05:27PM	TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock (GlobeNewswire)
Jul-20-21 08:05AM	TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award (GlobeNewswire) +5.10%
Jun-30-21 08:05AM	TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award (GlobeNewswire)
Jun-29-21 08:05AM	TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma (GlobeNewswire)
Jun-28-21 01:04PM	Is TRACON Pharmaceuticals Inc (TCON) A Good Stock To Buy? (Insider Monkey)
Jun-18-21 10:08AM	3 Strong Buy Stocks Under $10 With Over 100% Upside Potential (TipRanks) +10.17%
Jun-04-21 09:01AM	TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting (GlobeNewswire)
Jun-01-21 08:05AM	TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial (GlobeNewswire)

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
THEUER CHARLES	President and CEO	Apr 27 '23	Buy	0.75	47,000	35,250	399,417	Apr 28 06:00 AM
THEUER CHARLES	President and CEO	Apr 26 '23	Buy	0.66	3,999	2,639	352,417	Apr 28 06:00 AM

Open in Screener

ETON

Eton Pharmaceuticals Inc

Apr 24 • 04:00PM ET

3.21

Dollar change -0.07
Percentage change -2.13	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ETON Eton Pharmaceuticals Inc daily Stock Chart

Held by: VTI VXF IWC DFAS

Index	-	P/E	-	EPS (ttm)	-0.04	Insider Own	12.68%	Shs Outstand	25.69M	Perf Week	2.23%
Market Cap	82.46M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	22.43M	Perf Month	-17.27%
Income	-0.94M	PEG	-	EPS next Q	-	Inst Own	27.81%	Short Float	0.98%	Perf Quarter	-27.87%
Sales	31.64M	P/S	2.61	EPS this Y	-	Inst Trans	6.71%	Short Ratio	3.55	Perf Half Y	-17.05%
Book/sh	0.60	P/B	5.33	EPS next Y	-	ROA	-3.30%	Short Interest	0.22M	Perf Year	-8.29%
Cash/sh	0.83	P/C	3.86	EPS next 5Y	-	ROE	-6.56%	52W Range	2.42 - 5.81	Perf YTD	-26.71%
Dividend Est.	-	P/FCF	12.09	EPS past 5Y	63.71%	ROI	-6.04%	52W High	-44.75%	Beta	1.20
Dividend TTM	-	Quick Ratio	1.60	Sales past 5Y	11165.96%	Gross Margin	66.56%	52W Low	32.64%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	1.65	EPS Y/Y TTM	89.85%	Oper. Margin	-3.76%	RSI (14)	35.38	Volatility	4.91% 5.80%
Employees	30	Debt/Eq	0.35	Sales Y/Y TTM	48.90%	Profit Margin	-2.96%	Recom	1.00	Target Price	10.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-343.33%	Payout	-	Rel Volume	0.15	Prev Close	3.28
Sales Surprise	-5.03%	EPS Surprise	-125.00%	Sales Q/Q	-13.94%	Earnings	Mar 14 AMC	Avg Volume	62.08K	Price	3.21
SMA20	-7.20%	SMA50	-18.69%	SMA200	-20.39%	Trades		Volume	9,117	Change	-2.13%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-21	Resumed	B. Riley Securities	Buy	$10
Jan-04-21	Reiterated	H.C. Wainwright	Buy	$20 → $15
Sep-20-19	Initiated	B. Riley FBR	Buy	$13.50
Jun-10-19	Initiated	H.C. Wainwright	Buy	$15

Mar-22-24 02:20AM	Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE (ACCESSWIRE) +9.39%
02:00AM	Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE for Phenylketonuria (GlobeNewswire)
Mar-15-24 03:10PM	Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript (Insider Monkey) -13.68%
09:34AM	Q4 2023 Eton Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 08:55PM	ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:35PM	Loading…
05:35PM	Eton Pharmaceuticals Inc (ETON) Reports Robust Sales Growth and Pipeline Progress in Q4 and ... (GuruFocus.com)
05:15PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-29-24 04:01PM	Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024 (GlobeNewswire)
Feb-26-24 08:19AM	Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-21-24 06:50AM	Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation (GlobeNewswire)
Feb-02-24 06:50AM	Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules (GlobeNewswire)
Jan-16-24 07:52AM	3 Pharma Stocks for January 2024 Profits (Entrepreneur: Stocks) -6.41%
Nov-11-23 11:09AM	Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:01PM	Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire)
06:50AM	Loading…
Oct-30-23 06:50AM	Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 (GlobeNewswire)
Oct-23-23 05:16AM	Eton Pharma (ETON) to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-18-23 08:00AM	SWK Holdings Highlights Recent Achievements and Provides Portfolio Update (PR Newswire)
Oct-04-23 06:50AM	Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone (GlobeNewswire)
Sep-22-23 12:04PM	Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy (Zacks)
Sep-20-23 09:40AM	Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-12-23 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Eton Pharmaceuticals, Inc. (ETON) (Zacks)
Aug-25-23 11:36AM	Eton Pharmaceuticals (ETON): A Modestly Undervalued Stock Worth Your Attention (GuruFocus.com)
Aug-23-23 06:50AM	Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-16-23 09:15AM	Eton Pharmaceuticals, Inc. (ETON) Hits Fresh High: Is There Still Room to Run? (Zacks) -8.44%
Aug-13-23 07:52AM	Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 12:44PM	Q2 2023 Eton Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +38.08%
Aug-10-23 05:40PM	Eton Pharmaceuticals, Inc. (ETON) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-08-23 10:50AM	Techne (TECH) Meets Q4 Earnings Estimates (Zacks)
04:05PM	Loading…
Aug-01-23 04:05PM	Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (GlobeNewswire)
Jul-17-23 04:05PM	SWK Holdings Highlights Recent Achievements and Provides Portfolio Update (PR Newswire)
Jul-15-23 08:40AM	The past three years for Eton Pharmaceuticals (NASDAQ:ETON) investors has not been profitable (Simply Wall St.)
Jun-28-23 06:50AM	Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection (GlobeNewswire) -17.33%
May-16-23 11:35AM	Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 05:35PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Eton Pharmaceuticals Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-10-23 06:50AM	Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution) (GlobeNewswire)
May-03-23 04:05PM	Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 (GlobeNewswire)
Apr-19-23 11:22AM	Getting In Cheap On Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Might Be Difficult (Simply Wall St.)
Mar-22-23 07:17AM	When Will Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Breakeven? (Simply Wall St.)
Mar-18-23 02:03AM	Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 05:25PM	Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Surpass Estimates (Zacks) +7.89%
04:01PM	Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results (GlobeNewswire)
Mar-15-23 06:50AM	Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600 (GlobeNewswire)
Mar-07-23 04:05PM	Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023 (GlobeNewswire)
Feb-08-23 12:00PM	Eton Pharmaceuticals, Inc. (ETON) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Feb-05-23 07:30AM	Shareholders in Eton Pharmaceuticals (NASDAQ:ETON) are in the red if they invested three years ago (Simply Wall St.)
Jan-31-23 08:00AM	SWK Holdings Provides Portfolio Update Highlighting Recent Achievements (PR Newswire)
Jan-25-23 10:00AM	Best Momentum Stocks to Buy for January 25th (Zacks)
07:21AM	New Strong Buy Stocks for January 25th (Zacks)
Jan-24-23 12:26PM	Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic (Zacks)
Jan-23-23 11:01AM	Amarin Corporation (AMRN) Down 13% in One Week: Here's Why (Zacks)
10:00AM	Best Momentum Stocks to Buy for January 23rd (Zacks)
07:36AM	New Strong Buy Stocks for January 23rd (Zacks)
Jan-12-23 10:34AM	ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection (Zacks) -5.41%
Jan-11-23 07:27AM	Etons stock rallies as FDA reviews treatment for alcohol poisoning (MarketWatch) +13.85%
06:50AM	Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection (GlobeNewswire)
Nov-23-22 12:37PM	Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation (Zacks)
Nov-22-22 12:45PM	bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals (Zacks)
Nov-16-22 10:33AM	Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study (Zacks)
05:34AM	Eton Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 05:45PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Edited Transcript of ETON.OQ earnings conference call or presentation 10-Nov-22 9:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 04:05PM	Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022 (GlobeNewswire)
Oct-18-22 04:05PM	SWK Holdings Provides Portfolio Update Highlighting Recent Achievements (PR Newswire)
06:50AM	Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference (GlobeNewswire)
Sep-27-22 09:05AM	60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago (ACCESSWIRE)
Sep-13-22 09:00AM	Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution (GlobeNewswire)
Aug-30-22 04:05PM	Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 05:35PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-08-22 10:00AM	Analysts Estimate Fortress Biotech (FBIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Aug-04-22 10:00AM	Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: Should You Buy? (Zacks)
Aug-02-22 08:00AM	Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022 (GlobeNewswire)
Jul-18-22 08:09AM	Eton's stock gains 16% after announcing FDA approval of epilepsy drug (MarketWatch) +8.60%
07:05AM	Eton Pharmaceuticals Announces FDA Approval of ZONISADE (Zonisamide Oral Suspension) (GlobeNewswire)
Jun-24-22 09:45AM	Eton Pharma Shares Tick Higher After Offloading Hospital Products (Benzinga)
07:30AM	Eton Pharmaceuticals Announces Sale of Hospital Products (GlobeNewswire)
Jun-13-22 12:28PM	Eton Pharmaceuticals (NASDAQ:ETON) shareholders have endured a 62% loss from investing in the stock three years ago (Simply Wall St.)
May-13-22 09:08AM	Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Profit Outlook (Simply Wall St.) +7.61%
May-12-22 05:15PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -5.86%
04:02PM	Eton Pharmaceuticals Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-10-22 05:45PM	Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-05-22 07:25PM	Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
03:00PM	Analysts Estimate Eton Pharmaceuticals, Inc. (ETON) to Report a Decline in Earnings: What to Look Out for (Zacks)
May-03-22 04:02PM	Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022 (GlobeNewswire)
09:15AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-12-22 10:03AM	Analysts Just Published A Bright New Outlook For Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) (Simply Wall St.)
Apr-11-22 04:01PM	Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer (GlobeNewswire) -10.35%
07:30AM	Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection (GlobeNewswire)
Mar-16-22 04:02PM	Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results (GlobeNewswire)
Mar-14-22 07:00AM	Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL) (GlobeNewswire)
Mar-10-22 05:25PM	Clearside Biomedical, Inc. (CLSD) Q4 Earnings and Revenues Beat Estimates (Zacks)
Mar-08-22 08:00AM	Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022 (GlobeNewswire)
Jan-10-22 05:19AM	Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Dec-20-21 07:30AM	Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid) (GlobeNewswire)
Nov-26-21 04:43AM	Eton Pharmaceuticals (NASDAQ:ETON) shareholders have endured a 42% loss from investing in the stock a year ago (Simply Wall St.)
Nov-18-21 02:04PM	Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director (GlobeNewswire)

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Open in Screener

TARA

Protara Therapeutics Inc

Apr 24 • 04:00PM ET

2.82

Dollar change -0.18
Percentage change -6.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

TARA Protara Therapeutics Inc daily Stock Chart

Held by: VTI VXF IWC DFSU

Index	-	P/E	-	EPS (ttm)	-3.57	Insider Own	19.88%	Shs Outstand	11.36M	Perf Week	3.30%
Market Cap	32.23M	Forward P/E	-	EPS next Y	-4.13	Insider Trans	0.00%	Shs Float	9.16M	Perf Month	-29.32%
Income	-40.42M	PEG	-	EPS next Q	-0.92	Inst Own	52.16%	Short Float	0.71%	Perf Quarter	43.15%
Sales	0.00M	P/S	-	EPS this Y	-1.85%	Inst Trans	-4.11%	Short Ratio	0.26	Perf Half Y	107.35%
Book/sh	6.01	P/B	0.47	EPS next Y	-13.59%	ROA	-42.05%	Short Interest	0.07M	Perf Year	-21.45%
Cash/sh	5.74	P/C	0.49	EPS next 5Y	-	ROE	-47.44%	52W Range	1.04 - 5.24	Perf YTD	50.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	39.98%	ROI	-55.52%	52W High	-46.18%	Beta	1.79
Dividend TTM	-	Quick Ratio	11.17	Sales past 5Y	0.00%	Gross Margin	-	52W Low	171.15%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	11.17	EPS Y/Y TTM	39.08%	Oper. Margin	0.00%	RSI (14)	36.36	Volatility	11.11% 9.71%
Employees	27	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	27.80
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	73.99%	Payout	-	Rel Volume	1.68	Prev Close	3.00
Sales Surprise	-	EPS Surprise	1.91%	Sales Q/Q	-	Earnings	Mar 13 BMO	Avg Volume	251.03K	Price	2.82
SMA20	-17.00%	SMA50	-24.19%	SMA200	17.44%	Trades		Volume	422,081	Change	-6.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-23	Resumed	Guggenheim	Buy	$22
Jun-04-21	Initiated	H.C. Wainwright	Buy	$40
Feb-17-21	Initiated	Oppenheimer	Outperform	$43
Oct-19-20	Initiated	Cowen	Outperform	$50
Jul-29-20	Initiated	Guggenheim	Buy	$50

Apr-12-24 09:55AM	Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-05-24 08:04AM	Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing (GlobeNewswire) -9.70%
08:02AM	Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC (GlobeNewswire)
Mar-13-24 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Feb-28-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -7.45%
Jan-31-24 07:30AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-30-23 08:30AM	Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-23 09:43AM	Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results (GuruFocus.com) +11.57%
08:00AM	Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-23-23 08:00AM	Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Sep-20-23 08:30AM	Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ (GlobeNewswire)
Sep-05-23 07:30AM	Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 08:00AM	Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-15-23 08:00AM	Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ (GlobeNewswire)
08:00AM	Loading…
May-04-23 08:00AM	Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-02-23 08:00AM	Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Apr-28-23 08:00AM	Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development (GlobeNewswire)
Mar-08-23 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-23 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.76%
Feb-02-23 08:00AM	Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-30-23 08:00AM	Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer (GlobeNewswire)
Dec-01-22 08:00AM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-22 08:00AM	Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Oct-24-22 08:35AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Sep-06-22 08:00AM	Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-09-22 08:00AM	Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Jun-21-22 08:00AM	Protara Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire)
May-26-22 05:11PM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-17-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:32AM	Loading…
07:32AM	Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely? (Simply Wall St.)
May-12-22 08:00AM	Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations (GlobeNewswire)
May-05-22 08:00AM	Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Apr-11-22 09:55AM	Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect? (Zacks) -6.17%
Mar-24-22 08:00AM	Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Mar-23-22 10:00AM	Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect? (Zacks) +5.06%
Mar-09-22 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview (GlobeNewswire)
Mar-08-22 05:50AM	Protara Therapeutics, Inc. (NASDAQ:TARA) insider upped their holding by 222% earlier this year (Simply Wall St.)
Mar-02-22 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.67%
Feb-01-22 08:00AM	Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference (GlobeNewswire) +8.25%
Jan-10-22 08:00AM	Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer (GlobeNewswire)
Jan-04-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-08-21 11:15AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-04-21 08:00AM	Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Oct-25-21 04:45PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-12-21 07:00AM	Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer (GlobeNewswire) +11.85%
Sep-17-21 04:05PM	Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire)
Sep-13-21 07:00AM	Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
Sep-09-21 10:31AM	A number of insiders bought Protara Therapeutics, Inc. (NASDAQ:TARA) stock last year, which is great news for shareholders (Simply Wall St.)
Sep-07-21 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-05-21 08:00AM	Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Jul-07-21 08:00AM	Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Jun-22-21 07:30AM	ProBility Media Provides Corporate Update (PR Newswire)
Jun-10-21 08:00AM	Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors (GlobeNewswire)
May-13-21 08:00AM	Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences (GlobeNewswire)
May-06-21 07:30AM	Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview (GlobeNewswire) -5.69%
Apr-23-21 07:00AM	Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations (GlobeNewswire) -18.41%
Apr-19-21 04:09PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-12-21 11:12AM	The Dip in These 3 Stocks Is a Buying Opportunity, Say Analysts (TipRanks)
Mar-30-21 07:01AM	Do Insiders Own Lots Of Shares In Protara Therapeutics, Inc. (NASDAQ:TARA)? (Simply Wall St.)
Mar-11-21 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview (GlobeNewswire) +6.40%
Mar-10-21 08:00AM	Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire)
Feb-04-21 08:00AM	Protara Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire)
Feb-02-21 08:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors (GlobeNewswire)
Dec-16-20 11:07PM	Is TARA A Good Stock To Buy Now? (Insider Monkey)
Dec-07-20 04:30PM	Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer (GlobeNewswire)
Dec-03-20 07:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-20 07:00AM	Protara Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire)
Nov-12-20 07:15AM	Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview (GlobeNewswire)
Nov-11-20 07:00AM	Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference (GlobeNewswire)
Nov-04-20 07:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-28-20 03:12PM	What Type Of Shareholders Make Up Protara Therapeutics, Inc.'s (NASDAQ:TARA) Share Registry? (Simply Wall St.)
Sep-22-20 08:13AM	Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock (GlobeNewswire)
Sep-21-20 04:01PM	Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock (GlobeNewswire) -7.97%
Sep-08-20 07:00AM	Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications (GlobeNewswire) -6.09%
Sep-02-20 05:49PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-03-20 07:00AM	Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview (GlobeNewswire)
Jul-28-20 07:00AM	Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations (GlobeNewswire) +5.29%
Jul-24-20 07:00AM	Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors (GlobeNewswire)
Jul-03-20 06:34PM	Hedge Funds Have Never Been This Bullish On Protara Therapeutics, Inc. (TARA) (Insider Monkey)
Jul-02-20 07:59PM	CORRECTION Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-20 04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.74%
May-26-20 08:30AM	Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease (GlobeNewswire) +13.98%
May-13-20 08:00AM	Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview (GlobeNewswire) -8.46%
May-11-20 08:38AM	ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics (GlobeNewswire)
May-05-20 04:05PM	ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-20 07:00AM	ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-20 08:00AM	ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer (GlobeNewswire)

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Open in Screener

HROW

Harrow Inc

Apr 24 • 04:00PM ET

10.27

Dollar change -0.05
Percentage change -0.48	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO VHT IWC VTWG ITOT FHLC

Index	RUT	P/E	-	EPS (ttm)	-0.75	Insider Own	14.99%	Shs Outstand	35.17M	Perf Week	-13.11%
Market Cap	363.15M	Forward P/E	17.31	EPS next Y	0.59	Insider Trans	3.75%	Shs Float	30.06M	Perf Month	-14.42%
Income	-24.41M	PEG	-	EPS next Q	-0.20	Inst Own	65.28%	Short Float	20.36%	Perf Quarter	7.43%
Sales	130.19M	P/S	2.79	EPS this Y	57.00%	Inst Trans	-4.54%	Short Ratio	13.53	Perf Half Y	-27.37%
Book/sh	2.00	P/B	5.13	EPS next Y	283.98%	ROA	-10.41%	Short Interest	6.12M	Perf Year	-59.29%
Cash/sh	2.34	P/C	4.39	EPS next 5Y	15.00%	ROE	-49.84%	52W Range	7.60 - 28.25	Perf YTD	-8.30%
Dividend Est.	-	P/FCF	152.58	EPS past 5Y	-	ROI	-9.39%	52W High	-63.65%	Beta	0.56
Dividend TTM	-	Quick Ratio	2.60	Sales past 5Y	27.34%	Gross Margin	69.55%	52W Low	35.13%	ATR (14)	0.68
Dividend Ex-Date	-	Current Ratio	2.82	EPS Y/Y TTM	-44.20%	Oper. Margin	0.62%	RSI (14)	33.67	Volatility	6.36% 5.87%
Employees	315	Debt/Eq	2.71	Sales Y/Y TTM	46.95%	Profit Margin	-18.75%	Recom	1.00	Target Price	25.65
Option/Short	Yes / Yes	LT Debt/Eq	2.70	EPS Q/Q	-822.91%	Payout	-	Rel Volume	0.87	Prev Close	10.32
Sales Surprise	-3.97%	EPS Surprise	-500.46%	Sales Q/Q	78.83%	Earnings	Mar 19 AMC	Avg Volume	452.40K	Price	10.27
SMA20	-16.96%	SMA50	-11.17%	SMA200	-21.99%	Trades		Volume	394,039	Change	-0.48%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-11-24	Initiated	Craig Hallum	Buy	$24
Sep-08-22	Resumed	B. Riley Securities	Buy	$17
Oct-14-21	Resumed	B. Riley Securities	Buy	$16
Sep-24-21	Initiated	Aegis Capital	Buy	$15
Jul-02-21	Initiated	Ladenburg Thalmann	Buy	$14.25

Apr-02-24 08:16AM	Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing (Business Wire)
Mar-21-24 09:55AM	Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 09:52PM	HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
06:51PM	Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023 (GuruFocus.com)
05:45PM	Harrow Announces Fourth Quarter and Year-End 2023 Financial Results (Business Wire)
06:35AM	Loading…
Mar-13-24 06:35AM	Harrow (HROW) Fell on Lowering the Guidance (Insider Monkey)
Mar-05-24 07:00AM	Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024 (Business Wire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-21-24 06:47AM	Heres How Harrow (HROW) Weighed on SRK Capitals Performance (Insider Monkey)
Feb-15-24 04:01PM	Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products (Business Wire)
Jan-29-24 07:00AM	Harrow Announces New Appointments to its Board of Directors (Business Wire)
Jan-11-24 07:00AM	Harrow Announces Availability of VEVYE (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease (Business Wire)
Jan-03-24 07:15AM	Melt Pharmaceuticals Provides Corporate Update (Business Wire)
07:00AM	Harrow Partners with Leading Healthcare Market Access Technology Platforms (Business Wire)
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
07:00AM	Loading…
Nov-29-23 07:00AM	Harrow Completes Transfer of the TRIESENCE New Drug Application (Business Wire)
Nov-20-23 07:00AM	Harrow to Present at Two Investor Conferences in November (Business Wire) +5.58%
Nov-14-23 12:56PM	Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript (Insider Monkey) -36.01%
Nov-13-23 05:07PM	Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023 (GuruFocus.com)
04:01PM	Harrow Announces Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 08:00AM	Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023 (Business Wire)
Oct-24-23 07:00AM	Harrow Completes Transfer of NDAs and Launches FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, and ZERVIATE in the U.S. (Business Wire)
Sep-29-23 08:00AM	Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. (Business Wire)
Sep-26-23 08:00AM	Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation (Business Wire) -5.20%
Sep-21-23 01:03PM	Opaleye Management Inc. Reduces Stake in Harrow Health Inc. (GuruFocus.com)
Aug-11-23 01:05PM	Harrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:54AM	Q2 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents) -15.45%
Aug-09-23 04:14PM	Harrow: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Harrow Announces Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 07:00AM	Harrow Launches VIGAMOX® in the U.S. (Business Wire)
02:56PM	Loading…
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-26-23 03:42PM	Harrow Health inks deals for the rights to eight medications (American City Business Journals)
09:00AM	Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023 (Business Wire)
Jul-20-23 10:29AM	Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength? (Zacks)
Jul-19-23 12:17PM	Why Shares of Harrow Health Are Jumping Wednesday (Motley Fool) +17.84%
07:00AM	Harrow Prices $60 Million Public Offering of Common Stock (Business Wire)
Jul-18-23 05:00PM	Harrow Acquires Santens Branded Ophthalmic Portfolio (Business Wire)
04:05PM	Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance (Business Wire)
04:04PM	Harrow Announces Proposed Public Offering of Common Stock (Business Wire)
04:01PM	Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq (Business Wire)
Jul-05-23 06:15PM	Harrow Health (HROW) Gains As Market Dips: What You Should Know (Zacks)
Jun-29-23 06:15PM	Harrow Health (HROW) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-23-23 06:15PM	Harrow Health (HROW) Flat As Market Sinks: What You Should Know (Zacks)
Jun-16-23 06:00PM	Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know (Zacks)
May-17-23 08:00AM	Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023 (Business Wire)
May-16-23 11:57AM	Harrow Health, Inc. (NASDAQ:HROW) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-15-23 11:21AM	Analysts Initiate Coverage: 5 Stocks for Higher Returns (Zacks) -5.22%
May-12-23 01:48PM	Why Shares of Harrow Health Are Slumping Friday (Motley Fool) -18.58%
06:26AM	Q1 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 05:15PM	Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:29PM	Harrow: Q1 Earnings Snapshot (AP Finance)
04:01PM	Harrow Announces First Quarter 2023 Financial Results (Business Wire)
May-08-23 12:07PM	Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing? (Zacks)
May-04-23 08:00AM	Harrow to Launch FDA-Approved IHEEZO at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (Business Wire)
04:59AM	Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta (Zacks)
May-03-23 06:44AM	5 Stocks With Recent Price Strength That Still Have Upside (Zacks)
May-02-23 04:42PM	Use New Analyst Coverage to Find Great Momentum Stocks to Buy in May (Zacks)
09:40AM	Is HCA Healthcare (HCA) Outperforming Other Medical Stocks This Year? (Zacks)
07:00AM	Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S. (Business Wire)
May-01-23 08:50AM	Here's Why Momentum in Harrow (HROW) Should Keep going (Zacks)
Apr-28-23 06:00PM	Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know (Zacks)
05:00AM	Zacks.com featured highlights Harrow Health and Disc Medicine Opco (Zacks)
Apr-27-23 08:05AM	2 Stocks in Focus as Analysts Initiate Coverage (Zacks)
08:00AM	Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-24-23 08:43AM	Harrow Health and CDW have been highlighted as Zacks Bull and Bear of the Day (Zacks)
07:09AM	Bull Of The Day: Harrow Health (HROW) (Zacks)
Apr-20-23 08:31AM	5 Small Hidden Gems to Pick From a Rangebound Wall Street (Zacks)
Apr-19-23 06:15PM	Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know (Zacks)
08:31AM	Zacks.com featured highlights include Riley Exploration Permian, Harrow Health, Crawford, Tecnoglass and Lantheus Holdings (Zacks)
Apr-18-23 06:24AM	5 Stocks With Recent Price Strength to Maximize Your Gains (Zacks)
Apr-14-23 08:50AM	Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength (Zacks)
Apr-13-23 06:15PM	Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-12-23 09:40AM	Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year? (Zacks)
Apr-09-23 04:04PM	A New Roster of Top Stock-Fund Managers (The Wall Street Journal)
Apr-05-23 09:34AM	4 Medical Stocks to Buy as Rate Hike Cycle Nears End (Zacks)
Apr-04-23 05:37AM	Zacks.com featured highlights Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus (Zacks)
Apr-03-23 06:53AM	5 Stocks With Recent Price Strength Amid March Rally (Zacks)
Mar-29-23 08:50AM	Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Mar-28-23 02:59PM	B. Riley Leads Financing to Support Harrow Health Acquisition (PR Newswire)
07:00AM	Harrow Announces New $100 Million Secured Credit Facility with Oaktree (Business Wire)
Mar-27-23 08:51AM	Harrow Health, Inc. (NASDAQ:HROW) Q4 2022 Earnings Call Transcript (Insider Monkey) +16.50%
Mar-24-23 05:42AM	Q4 2022 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.78%
Mar-23-23 04:06PM	Harrow Announces Fourth Quarter and Year-End 2022 Financial Results (Business Wire)
Mar-13-23 07:00AM	Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% (Business Wire)
Mar-06-23 08:00AM	Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance (Business Wire)
Mar-02-23 08:00AM	Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023 (Business Wire)
Feb-16-23 06:42AM	Is Harrow Health (HROW) an Undervalued Stock? (Insider Monkey) +5.41%
Feb-15-23 07:00AM	Harrow Launches Next-Generation Compounded Atropine Formulations (Business Wire)
Feb-03-23 08:50AM	Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +8.29%
Feb-02-23 06:30AM	Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023 (Business Wire) +6.53%
Jan-23-23 07:00AM	Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products (Business Wire)
Jan-21-23 07:33AM	Investing in Harrow Health (NASDAQ:HROW) five years ago would have delivered you a 752% gain (Simply Wall St.)
Jan-18-23 08:50AM	Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why (Zacks)
Jan-05-23 07:00AM	Harrow Announces Availability of Fortisite Formulations for In-Office Use (Business Wire)
Dec-25-22 07:24AM	Trade Alert: The CEO & Chairman of the Board Of Harrow Health, Inc. (NASDAQ:HROW), Mark Baum, Has Just Spent US$335k Buying 1.8% More Shares (Simply Wall St.)
Dec-21-22 09:21AM	Melt Pharmaceuticals MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study (Business Wire) +10.57%
Dec-16-22 07:00AM	Harrow Secures Capital to Close Recently Announced Acquisition (Business Wire)
Dec-14-22 03:24PM	Harrow Health inks $175 million deal for the rights to five medications (American City Business Journals) +15.05%
09:41AM	Harrow Health Acquires Rights To Novartis' Five Approved Ophthalmic Products (Benzinga)
06:32AM	Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and "BB" Rating from Egan-Jones (Business Wire)

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Apr 24 '24	Buy	10.15	8,285	84,093	3,795,000	Apr 24 04:40 PM
Opaleye Management Inc.	10% Owner	Apr 23 '24	Buy	10.29	11,715	120,547	3,786,715	Apr 24 04:40 PM
Opaleye Management Inc.	10% Owner	Apr 19 '24	Buy	10.56	29,400	310,390	3,775,000	Apr 19 06:24 PM
Opaleye Management Inc.	10% Owner	Mar 28 '24	Buy	12.82	50,000	641,000	3,745,600	Mar 28 06:07 PM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Mar 22 '24	Buy	11.59	9,000	104,310	2,137,525	Mar 25 07:00 AM
Opaleye Management Inc.	10% Owner	Mar 20 '24	Buy	9.65	50,600	488,290	3,695,600	Mar 22 11:52 AM
SAHAREK JOHN P.	CEO of ImprimisRx	Mar 01 '24	Option Exercise	8.75	5,000	43,750	254,803	Mar 06 06:06 AM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Feb 20 '24	Option Exercise	10.67	150,000	1,600,500	2,188,361	Feb 21 07:29 PM
BOLL ANDREW R.	CHIEF FINANCIAL OFFICER	Feb 20 '24	Option Exercise	10.67	45,000	480,150	586,569	Feb 21 07:29 PM
SAHAREK JOHN P.	CEO of ImprimisRx	Feb 20 '24	Option Exercise	10.67	30,000	320,100	262,419	Feb 21 07:30 PM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Feb 07 '24	Option Exercise	7.71	15,400	118,734	2,038,361	Feb 08 07:30 AM
BOLL ANDREW R.	CHIEF FINANCIAL OFFICER	Feb 07 '24	Option Exercise	7.71	7,400	57,054	541,569	Feb 08 07:30 AM
BAUM MARK L	Chief Executive Officer	Nov 16 '23	Buy	8.11	7,500	60,825	2,022,961	Nov 16 04:45 PM
Opaleye Management Inc.	10% Owner	Nov 15 '23	Buy	8.03	25,000	200,735	3,645,000	Nov 16 04:05 PM
Opaleye Management Inc.	10% Owner	Sep 20 '23	Buy	14.49	5,983	86,710	3,620,000	Sep 20 06:39 PM
Opaleye Management Inc.	10% Owner	Sep 19 '23	Buy	14.65	14,017	205,366	3,614,017	Sep 20 06:39 PM
Makary Martin A.	Director	Aug 14 '23	Buy	16.92	20,000	338,400	45,000	Aug 15 07:30 AM
BAUM MARK L	Chief Executive Officer	Aug 14 '23	Buy	17.05	5,800	98,890	2,015,461	Aug 15 07:30 AM

Open in Screener

OCUL

Ocular Therapeutix Inc

Apr 24 • 04:00PM ET

4.64

Dollar change -0.36
Percentage change -7.10	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

OCUL Ocular Therapeutix Inc daily Stock Chart

Held by: VTI VXF IWM IWO VTWO DWAS PTH IWC VTWG ITOT

Index	RUT	P/E	-	EPS (ttm)	-1.26	Insider Own	9.13%	Shs Outstand	148.63M	Perf Week	-38.72%
Market Cap	690.39M	Forward P/E	-	EPS next Y	-0.86	Insider Trans	21.76%	Shs Float	135.05M	Perf Month	-50.64%
Income	-80.74M	PEG	-	EPS next Q	-0.19	Inst Own	45.06%	Short Float	8.74%	Perf Quarter	15.84%
Sales	58.44M	P/S	11.81	EPS this Y	17.45%	Inst Trans	-1.60%	Short Ratio	5.08	Perf Half Y	100.22%
Book/sh	0.79	P/B	5.86	EPS next Y	-3.15%	ROA	-40.23%	Short Interest	11.81M	Perf Year	-25.08%
Cash/sh	1.32	P/C	3.52	EPS next 5Y	-	ROE	-127.64%	52W Range	2.00 - 11.31	Perf YTD	4.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.38%	ROI	-46.69%	52W High	-58.93%	Beta	1.44
Dividend TTM	-	Quick Ratio	6.59	Sales past 5Y	121.20%	Gross Margin	90.96%	52W Low	132.83%	ATR (14)	0.59
Dividend Ex-Date	-	Current Ratio	6.66	EPS Y/Y TTM	-9.25%	Oper. Margin	-140.96%	RSI (14)	16.84	Volatility	14.42% 7.81%
Employees	267	Debt/Eq	0.92	Sales Y/Y TTM	13.49%	Profit Margin	-138.14%	Recom	1.38	Target Price	15.50
Option/Short	Yes / Yes	LT Debt/Eq	0.90	EPS Q/Q	-71.51%	Payout	-	Rel Volume	1.70	Prev Close	5.00
Sales Surprise	-5.74%	EPS Surprise	-18.12%	Sales Q/Q	5.16%	Earnings	Mar 11 AMC	Avg Volume	2.32M	Price	4.64
SMA20	-39.99%	SMA50	-46.09%	SMA200	-5.63%	Trades		Volume	3,950,972	Change	-7.10%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-09-24	Initiated	BofA Securities	Buy	$15
Apr-21-23	Initiated	Robert W. Baird	Outperform	$18
Aug-10-22	Resumed	Berenberg	Buy	$15
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy	$17
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy	$27
Nov-13-20	Reiterated	Raymond James	Strong Buy	$15 → $25
Aug-10-20	Reiterated	H.C. Wainwright	Buy	$10 → $13
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Reiterated	H.C. Wainwright	Buy	$12 → $9
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform	$11 → $5
May-21-19	Downgrade	Cowen	Outperform → Market Perform	$13 → $3
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight	$22 → $24
Nov-15-18	Initiated	Raymond James	Strong Buy	$10
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy	$12
Jul-26-17	Initiated	H.C. Wainwright	Buy	$10
Jul-12-17	Reiterated	Cantor Fitzgerald	Overweight	$35 → $21
Jun-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-10-17	Initiated	Cantor Fitzgerald	Overweight	$35

Show Previous Ratings

Today 08:30AM	2 Small-Cap Growth Stocks With Room to Run (Motley Fool) -7.10%
Apr-18-24 03:37PM	Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder (Benzinga) -22.69%
07:00AM	Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy (GlobeNewswire)
Apr-16-24 04:30PM	The 3 Best Biotech Stocks to Buy Now: Q2 Edition (InvestorPlace)
07:00AM	Ocular Therapeutix Strengthens Clinical Team with Appointment of Key Retinal Leaders (GlobeNewswire)
07:00AM	Loading…
Apr-15-24 07:00AM	Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO (GlobeNewswire)
Apr-09-24 09:35AM	Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround (Zacks)
07:30AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics (GlobeNewswire)
Apr-06-24 10:00AM	Ocular Therapeutix Announces Positive Phase 2 PAXTRAVA Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting (GlobeNewswire)
Apr-01-24 10:09AM	Million-Dollar Bets: 3 Under-$15 Stocks With Massive Potential (InvestorPlace)
Mar-26-24 07:30AM	Ocular Therapeutix To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery) (GlobeNewswire)
Mar-13-24 06:38AM	Q4 2023 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 09:55AM	Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet (Zacks)
Mar-11-24 05:32PM	Ocular Therapeutix Inc Reports Growth Amidst Strategic Shifts (GuruFocus.com)
05:25PM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Loading…
04:26PM	Ocular Therapeutix: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Ocular Therapeutix Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Mar-05-24 07:30AM	Ocular Therapeutix to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024 (GlobeNewswire)
Mar-01-24 06:30PM	Criteo, Ocular Therapeutix, and More Stocks See Action From Activist Investors (Barrons.com) +6.86%
Feb-29-24 08:52AM	Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings? (Zacks)
Feb-28-24 01:40PM	Hedge Fund and Insider Trading News: Stan Druckenmiller, Warren Buffett, Brevan Howard Asset Management, Citadel LLC, AMN Healthcare Services Inc (AMN), Ocular Therapeutix Inc (OCUL), and More (Insider Monkey)
Feb-26-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great Choice (Zacks)
10:00AM	Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-25-24 02:02PM	3 Stocks to Buy That Are Up 100% or More in 2024 (InvestorPlace)
Feb-22-24 07:32AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer (GlobeNewswire) +28.99%
07:31AM	Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement (GlobeNewswire)
07:30AM	Ocular Therapeutix Announces Board of Directors and Leadership Updates (GlobeNewswire)
Feb-21-24 09:55AM	Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 64.63%: Here's is How to Trade (Zacks)
Feb-19-24 09:00AM	AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis (PR Newswire)
Feb-18-24 08:00PM	AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis (PR Newswire)
08:00AM	Loading…
Feb-15-24 08:00AM	Ocular Therapeutix Appoints Steve Meyers to Chief Commercial Officer (GlobeNewswire) +6.19%
Feb-13-24 07:37AM	Ocular Therapeutix Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI in Wet AMD (GlobeNewswire)
Feb-12-24 06:27AM	Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains? (Zacks)
Jan-30-24 09:55AM	Does Ocular Therapeutix (OCUL) Have the Potential to Rally 134.83% as Wall Street Analysts Expect? (Zacks)
Jan-25-24 08:00AM	Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI in Wet AMD (GlobeNewswire) +6.98%
Jan-10-24 08:44AM	Why Ocular Therapeutix (OCUL) Stock Might be a Great Pick (Zacks)
Jan-03-24 01:15PM	Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024 (Motley Fool) -5.61%
Dec-18-23 04:01PM	Ocular Therapeutix Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -6.74%
Dec-13-23 10:09PM	Ocular Therapeutix Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +12.09%
04:01PM	Ocular Therapeutix Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-08-23 05:18PM	Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2023 Earnings Call Transcript (Insider Monkey) -13.20%
08:00AM	Ocular Therapeutix to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Nov-07-23 06:47PM	Ocular Therapeutix: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Ocular Therapeutix Provides Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Nov-01-23 08:00AM	Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD (GlobeNewswire) +11.93%
07:06AM	Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains? (Zacks)
Oct-31-23 09:00AM	AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA in Patients after Cataract Surgery (PR Newswire) +15.38%
Oct-30-23 09:35PM	AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery (PR Newswire)
Oct-24-23 08:00AM	Ocular Therapeutix To Report Third Quarter 2023 Financial Results (GlobeNewswire) +5.60%
Oct-03-23 04:01PM	Ocular Therapeutix Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD (GlobeNewswire)
Sep-19-23 09:00PM	AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery (PR Newswire)
Sep-06-23 08:00AM	Ocular Therapeutix to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Aug-09-23 08:00AM	Ocular Therapeutix to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-08-23 11:13AM	Q2 2023 Ocular Therapeutix Inc Earnings Call (Thomson Reuters StreetEvents) -10.78%
Aug-07-23 07:15PM	Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:05PM	Ocular Therapeutix: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Ocular Therapeutix Provides Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Jul-24-23 08:00AM	Ocular Therapeutix To Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-14-23 06:59AM	Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength? (Zacks)
Jul-13-23 09:00AM	10 Best Rising Penny Stocks to Buy (Insider Monkey)
Jul-12-23 08:00AM	Ocular Therapeutix Announces Appointment of New Board Member (GlobeNewswire)
Jun-10-23 06:30PM	Ocular Therapeutix Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD (GlobeNewswire)
Jun-07-23 08:00AM	Ocular Therapeutix Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy (GlobeNewswire)
Jun-05-23 04:01PM	Ocular Therapeutix To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting (GlobeNewswire)
Jun-02-23 09:37AM	Ocular Therapeutix, Inc. (NASDAQ:OCUL) is definitely on the radar of institutional investors who own 45% of the company (Simply Wall St.) +7.79%
Jun-01-23 08:00AM	Ocular Therapeutix to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-23 11:42AM	3 Low-Priced Stocks -- And How I'm Trading Them (TheStreet.com)
06:21AM	Q1 2023 Ocular Therapeutix Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 06:15PM	Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:07PM	Ocular Therapeutix: Q1 Earnings Snapshot (AP Finance)
04:01PM	Ocular Therapeutix Provides First Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
08:00AM	Ocular Therapeutix to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-04-23 09:50AM	Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Intrinsic Value Is Potentially 32% Above Its Share Price (Simply Wall St.)
Apr-28-23 08:00AM	Ocular Therapeutix To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (GlobeNewswire)
Apr-24-23 08:00AM	Ocular Therapeutix To Report First Quarter 2023 Financial Results (GlobeNewswire)
Apr-14-23 04:01PM	Ocular Therapeutix To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
Apr-07-23 08:49AM	Ocular Therapeutix (NASDAQ:OCUL) shareholders have endured a 21% loss from investing in the stock five years ago (Simply Wall St.)
Mar-11-23 07:22AM	Downgrade: Here's How Analysts See Ocular Therapeutix, Inc. (NASDAQ:OCUL) Performing In The Near Term (Simply Wall St.)
Mar-08-23 08:50AM	What Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing' (Zacks)
07:21AM	Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:37AM	Ocular Therapeutix Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Mar-07-23 08:40AM	Q4 2022 Ocular Therapeutix Inc Earnings Call (Thomson Reuters StreetEvents) +5.29%
Mar-06-23 05:15PM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.58%
04:01PM	Ocular Therapeutix Provides Fourth Quarter and Year-End 2022 Results and Corporate Update (GlobeNewswire)
Feb-28-23 08:00AM	Ocular Therapeutix to Present at Cowens 43rd Annual Healthcare Conference (GlobeNewswire)
Feb-27-23 05:15PM	Chinook Therapeutics (KDNY) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-21-23 08:00AM	Ocular Therapeutix To Report Fourth Quarter and Year-End 2022 Financial Results (GlobeNewswire) -8.45%
Feb-16-23 05:15PM	Why Shares of Ocular Therapeutix Jumped This Week (Motley Fool)
Feb-13-23 05:52AM	Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD (Benzinga) +35.14%
Feb-11-23 08:00AM	Ocular Therapeutix Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD (GlobeNewswire)
Jan-06-23 08:00AM	Ocular Therapeutix Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones (GlobeNewswire) +16.40%
Dec-24-22 07:34AM	With 48% stake, Ocular Therapeutix, Inc. (NASDAQ:OCUL) seems to have captured institutional investors' interest (Simply Wall St.)
Nov-13-22 07:10AM	These Analysts Just Made A Neat Downgrade To Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Forecasts (Simply Wall St.)
Nov-08-22 08:00AM	Ocular Therapeutix to Participate at Three Upcoming Investor Conferences (Business Wire) -10.99%
05:38AM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised) (Zacks)
Nov-07-22 05:25PM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
05:25PM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised) (Zacks)
04:01PM	Ocular Therapeutix Reports Third Quarter 2022 Financial Results and Business Update (Business Wire)
Oct-24-22 06:00AM	Ocular Therapeutix To Report Third Quarter 2022 Financial Results (Business Wire)
Oct-17-22 08:11AM	Investors in Ocular Therapeutix (NASDAQ:OCUL) have unfortunately lost 63% over the last year (Simply Wall St.)

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SUMMER ROAD LLC	10% Owner	Feb 26 '24	Buy	7.52	930,851	7,000,000	8,591,401	Feb 27 04:43 PM
Mattessich Antony C.	President and CEO	Jan 31 '24	Sale	4.95	18,338	90,773	427,943	Feb 02 07:00 PM
Ozden Rabia Gurses	Chief Medical Officer	Jan 31 '24	Sale	4.95	7,764	38,432	92,767	Feb 02 07:02 PM
Strassburger Philip C.	General Counsel	Jan 31 '24	Sale	4.95	6,831	33,813	109,218	Feb 02 07:01 PM
Notman Donald	Chief Financial Officer	Jan 31 '24	Sale	4.95	6,433	31,843	139,932	Feb 02 07:03 PM
White Christopher G	Chief Business Officer	Jan 31 '24	Sale	4.95	5,147	25,478	89,619	Feb 02 07:01 PM
SUMMER ROAD LLC	10% Owner	Dec 14 '23	Buy	3.25	1,538,461	4,999,998	7,660,550	Dec 18 04:52 PM
Mattessich Antony C.	President and CEO	Aug 30 '23	Buy	3.81	6,500	24,765	6,500	Sep 05 08:27 AM
Ozden Rabia Gurses	Chief Medical Officer	Jul 07 '23	Sale	4.93	832	4,102	100,531	Jul 11 08:00 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

TCON

TRACON Pharmaceuticals Inc

ETON

Eton Pharmaceuticals Inc

TARA

Protara Therapeutics Inc

HROW

Harrow Inc

OCUL

Ocular Therapeutix Inc

Upgrade your FINVIZ experience